SOLO-3 Adds To AZ/MSD’s Lynparza’s Ovarian Cancer Success Tally But Impact Minimal
Companies plan to discuss SOLO-3 data with the US FDA after Lynparza shows a benefit in third-line ovarian cancer, but commercial impact will be slight.
You may also be interested in...
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
Clinicians and analysts have lauded spectacular results presented at ESMO from the SOLO-1 trial which strongly suggest that AstraZeneca's Lynparza should be the first-line maintenance treatment of choice for ovarian cancer patients with a BRCA mutation.
A couple of trials for two investigational late-stage breast cancer candidates from AstraZeneca have each produced encouraging data for a novel drug class where rivals have previously hit clinical buffers.